Nilkamal Limited has informed the Exchange regarding Board meeting held on May 14, 2025.
NILKAMAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nilkamal's board approved audited financial results for Q4 and FY25 (March 31, 2025) with an unmodified auditor's opinion from S R B C & Co LLP. Standalone revenue from operations grew to Rs. 3,23,931 lakhs (FY24: Rs. 3,13,411 lakhs), but net profit declined to Rs. 9,127 lakhs (FY24: Rs. 10,731 lakhs), with EPS at Rs. 61.16 (FY24: Rs. 71.91). The board recommended a final dividend of Rs. 20 (200%) per share, subject to shareholder approval at the 39th AGM scheduled for July 18, 2025. The company also announced the acquisition of the healthcare business of Imedfurns Private Limited for Rs. 4 crore (payable over 4 years) and the continuation of Mr. Sharad V. Parekh as Chairman for another four years.
Despite modest revenue growth, the double-digit fall in annual net profit and EPS is a concern and may pressure the stock in the short term. The 200% final dividend and small healthcare acquisition provide some positive offsets but are unlikely to fundamentally shift the earnings narrative.